Ranking the Diabetes-related Safety Profile of Different Statin Drugs (opens in new tab)

For those of us tracking longevity, metabolic health is paramount. While statins remain the gold standard for reducing cardiovascular risk by lowering LDL-C, their “metabolic tax”—specifically the increased risk of incident diabetes—has been a known, yet often generalized, concern. A recent analysis of the FDA Adverse Event Reporting System (FAERS) database (2004–2022) provides a much-needed breakdown, offering a comparative look at how different statins stack up regarding their diabetes-rela...